In COVID-19 clinical update #115, Dr. Griffin discusses croup association with infection surge, rhinovirus co-circulation in children, shedding following vaccination, high vaccine efficacy in children 6 mo-5 yr, vaccine protection for hospitalized patients, convalescent plasma as post-exposure prophylaxis, real-world effectiveness of PAXLOVID, effectiveness of PAXLOVID in reducing hospitalization, infection rebound after PAXLOVID, relapse of symptomatic infection after PAXLOVID, remdesivir and bebtelovimab fact sheets for providers, guidelines on usage of anticoagulation drugs, long covid symptoms after vaccination, excess mortality in MA, infection sequelae and immunity, and post infection conditions among adults.
In this special episode, Dr. Griffin answers questions about the recent cases of monkeypox including their origin, clinical presentation, diagnosis, treatment, and overall risk.
TWiV reviews recent cases of monkeypox, presence of SARS-CoV-2 RNA but not infectious virus in feces, and the association of autoantibodies to interferons with severe COVID-19.
In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.
TWiV celebrates 900 episodes, Vincent gives the Richard R. Ernst lecture, and we discuss why inflammasome activation in infected macrophages drives severe COVID-19. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Click…
n COVID-19 clinical update #114, Dr. Griffin discusses early treatment with ivermectin, procalcitonin not a reliable biomarker, vaccine in 6-11 year olds, FDA limits use of Janssen vaccine, does site of vaccine booster matter, sniffer dogs, monoclonals for hospitalized patients, risk assessment for public events, Paxlovid eligibility, and persistence of pediatric anosmia,
TWiV explains why the concept of herd immunity might not apply to COVID-19, and the observation that smallpox vaccination causes an increase in skin bacteria that promote pathology and influence the immune response.
In COVID-19 clinical update #113, Dr. Griffin discusses tocilizumab use in hospitalized Patients, IL-6 inhibitors and mortality, Baricitinib in hospitalized patients, post-infection neurological sequelae, comparative effectiveness of Pfizer and Moderna vaccines, phase 2/3 study of Paxlovid, infection relapse following Paxlovid, pre-hospital administration of Remdesivir, and hospitalization with different variants.
TWiV explains a study of how climate change is predicted to increase cross-species viral transmission risk, and increased memory B cell potency and breadth after a SARS-CoV-2 mRNA vaccine boost.
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.